(secondQuint)Pediatric Arthritis Study of Certolizumab Pegol.

 The overall study consists of a Screening Period of up to 4 weeks and an Open-Label Treatment Period which will continue until the approval of the marketing application for the Polyarticular-course Juvenile Idiopathic Arthritis (JIA) indication in the subject's country or region or until further notice from UCB (approximately 4-6 years duration; depending on region).

 A Final Visit will be conducted 12 weeks after last dose of study medication.

 Overall, study visits will occur monthly during the first 6 months and every 2 months afterwards.

 All patients will receive active treatment with Certolizumab Pegol.

 The dose will depend on actual weight.

 Home dosing will be allowed between study visits.

 If less than 50 % of the study population achieves an adequate response to the treatment (American College of Rheumatology Pediatric 30 % (PedACR30) response) at Week 16, the study will be entirely discontinued.

.

 Pediatric Arthritis Study of Certolizumab Pegol@highlight

A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).

